Core 3: Biospecimens and Pathology Core
- Institution
- UNIVERSITY OF TX MD ANDERSON CAN CTR, TX
- Principal investigator
- Francisco Vega-Vazquez
- Funding
- $285K
- Duration
- 2025–2030
Moonbase score
Still being scored
Abstract
CORE 2. BIOSPECIMENS AND PATHOLOGY: ABSTRACT Histologic and molecular analyses of lymphoma tissue specimens are a cornerstone of each SPORE Project, as our investigators aim to close the knowledge gap regarding lymphoma biology across patient groups and propose novel diagnostic and therapeutic strategies. The expert hematopathologists directing the Biospecimens and Pathology Core (Core 2) will ensure accurate tissue collection, render pathologic characterization of lymphoma tumors, and provide critical support for all SPORE Projects through its comprehensive infrastructure for biospecimen collection, pathology review, multiplex imaging, and molecular analysis. In addition to using conventional histomorphologic, immunohistochemical and molecular techniques, Core 2 has also developed methods to create tissue derivatives (e.g., tissue microarrays, RNA, DNA) suitable for identification and validation of molecular markers that may contribute to lymphoma progression and disease resistance. To enhance the usability of specimens, Core 2 will digitize slides for hematoxylin and eosin (H&E), immunohistochemistry, and multiparametric imaging to generate a pathology image library accessible to all SPORE Project, Career Enhancement Program, and Developmental Research Program investigators. Core 2 will offer advanced imaging and immunophenotypic services crucial for molecular analyses. This includes multiplexed immunohistochemical and immunofluorescence staining, and spatial transcriptomics profiling with state-of-the-art technologies such as CODEX and COSMx 6k imaging. In addition, Core 2 will support development of patient-derived tumor xenografts (PDXs) with histopathologic characterization and creation of PDX-derived cell lines and organoids. Core 2 incorporates several innovative features in collaboration with Core 3 (Biostatistics and Bioinformatics), including a secure database that houses comprehensive information on collected biospecimens, patient demographics, clinical data, treatment history, and outcomes, as well as the establishment of novel technologies for cellular imaging. Core 2 will also work with Core 1 (Community Outreach and Engagement) to improve strategies for tissue collection in community and academic settings. Thus, Core 2 supports our SPORE to deliver critical resources and technological advancements in the field of lymphoma research focused on improving outcomes for populations.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF TX MD ANDERSON CAN CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of TX MD Anderson Can Ctr49
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
Khandan Keyomarsi · $428K · 2020–2026
- NIH · University of TX MD Anderson Can Ctr47
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Michael Andreeff · $461K · 2019–2027
- NIH · University of TX MD Anderson Can Ctr46
Modulation of intracellular lipid access by ATGL determines ferroptosis sensitivity in castration-resistant prostate cancer
Pham Hong Anh Cao · $39K · 2025–2027